Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 76% of retail investor accounts lose money when spread betting and/or trading CFDs with this provider. You should consider whether you understand how spread bets and CFDs work and whether you can afford to take the high risk of losing your money

76% of retail investor accounts lose money when spread betting and/or trading CFDs with this provider. You should consider whether you can afford to take the high risk of losing your money.

  • Updates
  • disruptive innovation

Top Stories

South-east Asia’s tech favourites lose over 69%

In today’s top stories, Bloomberg analysis shows that Southeast Asia’s tech unicorns have plummeted since going public, electric vehicle maker Rivian pauses a joint venture with Mercedes-Benz, and Microsoft acquires a 4% stake in the London Stock Exchange. Amgen has also agreed to acquire Horizon Therapeutics, while software firm Coupa is being acquired by Thoma Bravo.

Rivian pauses Mercedes-Benz joint venture

More bad news for EV maker Rivian [RIVN], which had to recall nearly all of its vehicles at the end of October. It has paused its joint venture with Mercedes-Benz [MBG.DE] to make electric vans in Europe. Rivian CEO RJ Scaringe said in a statement that the company wants to focus on risk-adjusted returns” on capital investments and the consumer business presents the most attractive near-term opportunities to maximise value”.

Microsoft buys 4% of London Stock Exchange

Microsoft [MSFT] has taken a 4% stake in the London Stock Exchange Group [LSEG] for £1.5bn. The two parties are set to work together over the next 10 years on cloud technology and data analytics, handling and infrastructure. The group said in a statement that the tie-up is expected to increase LSEGs revenue growth meaningfully over time as new products come on-stream”.

Amgen to buy Horizon Therapeutics

Drugmaker Amgen [AMGN] is set to acquire Horizon Therapeutics [HZNP] for approximately $26bn or $116.50 per share, Reuters reported. The deal will see Amgen add Horizons blockbuster thyroid eye drug Tepezza to its pipeline, which currently accounts for almost half of Horizons revenue. Amgens autoimmune and inflammatory diseases portfolio was boosted back in October when it completed the $3.7bn buyout of ChemoCentryx.

South-east Asia tech valuations plummet

The valuations of south-east Asias favourite tech unicorns have plummeted since going public, Bloomberg data shows. Ride-hailing firm Grabs [GRAB] market cap has dropped over 70%; food delivery and e-commerce group GoTos [GOTO.JK] by 74%; and e-commerce rival Bukalapaks [BUKA.JK] by 69%. Goldman Sachs analysts expect equities in the region to fall in the first half of 2023, before taking a "bungee jump" in the second, according to a note seen by CNBC.

Thoma Bravo targets Coupa Software

Private investment firm Thoma Bravo has announced that it will be acquiring Coupa Software [COUP] for $8bn. Rumours of the deal swirled on Monday morning, when the buyout received the approval of Billy Montana, partner and portfolio manager at Jackson Square Partners. An adequate takeout premium would represent immediate and certain value creation in an uncertain environment,” Montana wrote in an email last Friday.

Disclaimer Past performance is not a reliable indicator of future results.

CMC Markets is an execution-only service provider. The material (whether or not it states any opinions) is for general information purposes only, and does not take into account your personal circumstances or objectives. Nothing in this material is (or should be considered to be) financial, investment or other advice on which reliance should be placed. No opinion given in the material constitutes a recommendation by CMC Markets or the author that any particular investment, security, transaction or investment strategy is suitable for any specific person.

The material has not been prepared in accordance with legal requirements designed to promote the independence of investment research. Although we are not specifically prevented from dealing before providing this material, we do not seek to take advantage of the material prior to its dissemination.

CMC Markets does not endorse or offer opinion on the trading strategies used by the author. Their trading strategies do not guarantee any return and CMC Markets shall not be held responsible for any loss that you may incur, either directly or indirectly, arising from any investment based on any information contained herein.

*Tax treatment depends on individual circumstances and can change or may differ in a jurisdiction other than the UK.

Continue reading for FREE

  • Includes free newsletter updates, unsubscribe anytime. Privacy policy

Latest articles